Ivan Platzek1, Bettina Beuthien-Baumann2, Rainer Ordemann3, Jens Maus4, Georg Schramm4, Hagen H Kitzler5, Michael Laniado6, Jörg Kotzerke2, Jörg van den Hoff4. 1. Department of Radiology, Dresden University Hospital, Fetscherstr. 74, 01307 Dresden, Germany. Electronic address: ivan.platzek@uniklinikum-dresden.de. 2. Department of Nuclear Medicine, Dresden University Hospital, Dresden, Germany. 3. Department of Internal Medicine, Dresden University Hospital, Dresden, Germany. 4. Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany. 5. Department of Neuroradiology, Dresden University Hospital, Dresden, Germany. 6. Department of Radiology, Dresden University Hospital, Fetscherstr. 74, 01307 Dresden, Germany.
Abstract
RATIONALE AND OBJECTIVES: The purpose of this study was to evaluate the sensitivity and specificity of positron emission tomography/magnetic resonance imaging (PET/MR) with 18F-fluorodeoxyglucose (FDG) for nodal involvement in malignant lymphoma. MATERIALS AND METHODS: Twenty-seven patients with malignant lymphoma (16 men and 11 women; mean age, 45 years) were included in this retrospective study. The patients underwent FDG PET/MR after intravenous injection of FDG (176-357 MBq FDG, 282 MBq on average). Follow-up imaging and histology served as the standard of reference. RESULTS: One-hundred and twenty-seven (18.1%) of 702 lymph node stations were rated as having lymphoma involvement based on the standard of reference. One-hundred and twenty-four (17.7%) of 702 lymph node stations were rated as positive by FDG PET/MR. The sensitivity and specificity of FDG PET/MR for lymph node station involvement were 93.8% and 99.4%. CONCLUSIONS: FDG PET/MR is feasible for lymphoma staging and has a high sensitivity and specificity for nodal involvement in lymphoma. Comparison with PET/CT is necessary to determine whether FDG PET/MR can replace PET/CT for lymphoma staging.
RATIONALE AND OBJECTIVES: The purpose of this study was to evaluate the sensitivity and specificity of positron emission tomography/magnetic resonance imaging (PET/MR) with 18F-fluorodeoxyglucose (FDG) for nodal involvement in malignant lymphoma. MATERIALS AND METHODS: Twenty-seven patients with malignant lymphoma (16 men and 11 women; mean age, 45 years) were included in this retrospective study. The patients underwent FDG PET/MR after intravenous injection of FDG (176-357 MBq FDG, 282 MBq on average). Follow-up imaging and histology served as the standard of reference. RESULTS: One-hundred and twenty-seven (18.1%) of 702 lymph node stations were rated as having lymphoma involvement based on the standard of reference. One-hundred and twenty-four (17.7%) of 702 lymph node stations were rated as positive by FDG PET/MR. The sensitivity and specificity of FDG PET/MR for lymph node station involvement were 93.8% and 99.4%. CONCLUSIONS:FDG PET/MR is feasible for lymphoma staging and has a high sensitivity and specificity for nodal involvement in lymphoma. Comparison with PET/CT is necessary to determine whether FDG PET/MR can replace PET/CT for lymphoma staging.
Authors: Julian Kirchner; Cornelius Deuschl; Johannes Grueneisen; Ken Herrmann; Michael Forsting; Philipp Heusch; Gerald Antoch; Lale Umutlu Journal: Eur J Nucl Med Mol Imaging Date: 2017-02-04 Impact factor: 9.236
Authors: Ken Herrmann; Marcelo Queiroz; Martin W Huellner; Felipe de Galiza Barbosa; Andreas Buck; Niklaus Schaefer; Paul Stolzman; Patrick Veit-Haibach Journal: BMC Cancer Date: 2015-12-23 Impact factor: 4.430
Authors: Usman Bashir; Andrew Mallia; James Stirling; John Joemon; Jane MacKewn; Geoff Charles-Edwards; Vicky Goh; Gary J Cook Journal: Diagnostics (Basel) Date: 2015-07-21
Authors: Johannes Grueneisen; Lino Morris Sawicki; Benedikt Michael Schaarschmidt; Saravanabavaan Suntharalingam; Sara von der Ropp; Axel Wetter; Verena Ruhlmann; Harald H Quick; Michael Forsting; Lale Umutlu Journal: PLoS One Date: 2016-06-21 Impact factor: 3.240
Authors: Chiara Giraudo; Markus Raderer; Georgios Karanikas; Michael Weber; Barbara Kiesewetter; Werner Dolak; Ingrid Simonitsch-Klupp; Marius E Mayerhoefer Journal: Invest Radiol Date: 2016-03 Impact factor: 6.016